Compare Regeneron Pharmaceuticals Inc (REGN) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.41. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| REGN | XDTE | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $852.03 | $44.76 |
52-Week Low | $555.51 | $36.00 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
XDTE trades at $38.60, down 0.5% on the day, with technical indicators showing bearish momentum as moving averages signal selling pressure. The ETF's weekly dividend strategy has generated significant attention, with recent payouts ranging from $0.09 to $0.26 per share. However, financial ratios remain unavailable, limiting fundamental analysis. Recent news coverage highlights concerns about the sustainability of XDTE's high yield strategy and fee structure compared to alternatives.
The outlook for XDTE appears cautious due to questions about dividend sustainability and competitive fee pressures. While the weekly income strategy attracts yield-seeking investors, structural risks and bearish technical signals suggest limited near-term upside potential. Investors should weigh the high distribution yield against potential total return underperformance in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
